Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This study tests two drugs — binimetinib and imatinib — together for people with advanced or metastatic melanoma (skin cancer) that has a specific genetic mutation in a gene called KIT, which drives the cancer's growth. Both drugs target this pathway in different ways. **You may be eligible if...** - You have confirmed unresectable Stage III or IV melanoma - Your melanoma has been tested and confirmed to have a KIT mutation by a certified lab - You have measurable disease on imaging - Your blood counts and organ function are within acceptable ranges - You have progressed on prior standard treatments, or are unable to tolerate them **You may NOT be eligible if...** - Your melanoma does not have a KIT mutation - Your blood counts or organ function are inadequate - You have untreated or unstable brain metastases - Your overall health status is too poor (ECOG score greater than 2) Talk to your doctor to see if this trial is right for you.